Eli Lilly (LLY) Crushes Q2 and Raises Guidance Again — Can the Oral Pill Keep the Weight-Loss Machine Growing?
Eli Lilly topped Wall Street's estimates on both the top and bottom lines in Q2, powered by a 91% surge in Mounjaro sales, and raised full-year guidance for the second time this year. Shares jumped in premarket trading as investors weighed a beat-and-raise quarter against an already-lofty valuation